NALOXEGOL | NALOXEGOL | ATC A06AH03
METABOLISM OPIOID ANTAGONIST TREATMENT OF OPIOID-INDUCED CONSTIPATION PEGYLATED DERIVATIVE OF NALOXONE CNS PENETRATION OF NALOXEGOL IS EXPECTED TO BE NEGLIGIBLE | ORAL | Tmax 2 HOUR VD 1554 LITER PPB 4.2 PERCENT Cl 126 LITER / HOUR (EQN) HT 8.5 HOUR SOLUBILITY HIGH AQUEOUS SOLUBILITY ACROSS THE PHYSIOLOGIC PH RANGE | MU-OPIOID RECEPTOR | MU OPIOID RECEPTOR ANTAGONIST CHEMBL233 MU OPIOID RECEPTOR P35372 MU-TYPE OPIOID RECEPTOR HOMO SAPIENS MEMBRANE RECEPTOR 7TM1 PEPTIDE SHORT PEPTIDE OPIOID RECEPTOR | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |